We take a look at the approval of Relyvrio, the third approved treatment for ALS, and the first to show both a slowing of disease progression and extended survival.
More M&A and corporate strategic changes? Advances in Alzheimers? New offerings for NASH & depression? We take a peek into what to expect in pharma in 2023.